ReSTORE T Cell Engagers: Maintaining Immune Activation and Controlling CRS via Depletion of MDSC

Time: 11:00 am
day: Track B - Day 1 AM


  • AMV564, a bivalent T cell engager that targets MDSC, has shown monotherapy activity in solid tumor patients with limited evidence CRS
  • Consistent with these clinical findings, the cytokine profile in patients treated with AMV564 shows strong induction of IFNγ and cytokines and chemokines driving T cell trafficking and activation, with limited IL6
  • ReSTORE pipeline molecules provide additional specificity for tumor targets to address non-immunogenic solid tumors